Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma

Histopathology

Volumn 54, Issue 2, 2009, Pages 254-257

  Faratian, Dana ^a   Munro, Alison ^a   Twelves, Christopher ^a   Bartlett, John ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Biomarker; Breast cancer; HER2; Immunohistochemistry; Ki67; MIB 1; Oestrogen receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CELL MEMBRANE; CYTOPLASM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL MEMBRANE; CYTOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 58649100690     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03191.x     Document Type: Article

References (12)

1. van Diest PJ, van der WE, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J. Clin. Pathol. 2004 57 675 681.
2. Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl. Cancer Inst. 2007 99 167 170.
3. Dowsett M, Smith IE, Ebbs SR et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin. Cancer Res. 2006 12 1024s 1030s.
4. Hirokawa M, Carney JA. Cell membrane and cytoplasmic staining for MIB-1 in hyalinizing trabecular adenoma of the thyroid gland. Am. J. Surg. Pathol. 2000 24 575 578.
5. Hattori H. Sclerosing haemangioma of the lung is positive for MIB-1 in cell membrane and cytoplasmic staining pattern. Histopathology 2002 40 291 293.
6. Tashiro T, Hirokawa M, Harada H, Yokoyama S, Sano T. Cell membrane expression of MIB-1 in salivary gland pleomorphic adenoma. Histopathology 2002 41 559 561.
7. Leonardo E, Volante M, Barbareschi M et al. Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact? Appl. Immunohistochem. Mol. Morphol. 2007 15 220 223.
8. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984 133 1710 1715.
9. Schmidt MH, Broll R, Bruch HP, Duchrow M. The proliferation marker pKi-67 becomes masked to MIB-1 staining after expression of its tandem repeats. Histochem. Cell Biol. 2002 118 415 422.
10. Duchrow M, Schluter C, Wohlenberg C, Flad HD, Gerdes J. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif. 1996 29 1 12.
11. Schmidt MH, Rainer B, Bruch HP, Finniss S, Bogler O, Duchrow M. Proliferation marker pKi-67 occurs in different isoforms with various cellular effects. J. Cell. Biochem. 2004 91 1280 1292.
12. Ioachim E, Kamina S, Athanassiadou S, Agnantis NJ. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Anticancer Res. 1996 16 3141 3147.